Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2021  |  Volume : 19  |  Issue : 3  |  Page : 151-156

Effect of direct-acting antiviral treatment on decompensated Hepatitis C Virus cirrhosis

1 Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland; Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA
2 Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA
3 Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland; Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA

Correspondence Address:
Dr. Neha Jakhete
Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland Medical Center, Baltimore, Maryland
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/cmi.cmi_35_21

Rights and Permissions

Goals: The goal of the study is to assess the effect of direct-acting antivirals (DAAs) on the model for end-stage liver disease-sodium (MELD-Na) score and on specific decompensations related to hepatitis C virus (HCV) cirrhosis. The aim of our study was to identify a specific cohort of patients with cirrhosis, if any, that should be targeted for treatment with DAAs. Background: The development of DAAs has provided safe and well-tolerated treatment options for patients with advanced liver disease. However, controversy remains in terms of optimal timing of treatment and whether this treatment should be offered before or following liver transplantation. Methods: We identified all patients with HCV cirrhosis who initiated treatment with DAA therapy at Johns Hopkins Hospital between July 2014 and June 2016. We identified a subset of patients who had decompensated cirrhosis and recorded their MELD-Na scores and decompensations pre- and post-treatment. Results: Fifty-six patients achieved sustained virologic response with decompensated HCV cirrhosis. The group demonstrated a significant decrease in median MELD-Na score following treatment from 12 to 10.5. Furthermore, a significant percentage of patients experienced resolution of ascites following DAA therapy with 19 patients (35.2%) clearing their ascites posttreatment. Of the 19 patients who cleared ascites, MELD-Na score decreased from a median of 12 (interquartile range [IQR] 11–18) to 11 (IQR 8–14), P = 0.01. Conclusions: Our findings suggest that patients with ascites as their main decompensation should be considered for the treatment with DAAs, while awaiting liver transplant given that the MELD-Na score showed only modest improvement and thus would not affect liver transplant (LT) listing priority.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded138    
    Comments [Add]    

Recommend this journal